There is a clear and urgent medical need of developing new medicinal products for COVID-19
since there are poor pharmacological tools to block the progression of patients to cytokine
storm syndrome (CSS). To this aim, this Phase Ib clinical study (APTACOVID) pretends to
determine whether ApTOLL, in combination with the standard of care, is safe and shows any
biological effect) in those patients infected with SARS-CoV-2 who are not developed CSS yet.